MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC-Reference-Cited by-同舟云学术

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Published:2020-07-09 Issue:11 Volume:50 Page:1810-1819
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur. J. Immunol.

Author:

Koh Jiae¹²^ORCID,Kim Youjin³⁴,Lee Kyoung Young²,Hur Joon Young³,Kim Mi Soon²,Kim Boram²,Cho Hee Jin²,Lee Yeong Chan⁵,Bae Yeon Hee²,Ku Bo Mi²,Sun Jong‐Mu³,Lee Se‐Hoon¹³,Ahn Jin Seok³,Park Keunchil³,Ahn Myung‐Ju¹³

Affiliation:

1. Department of Health Sciences and Technology SAIHST Sungkyunkwan University Seoul Korea

2. Research Institute for Future Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea

3. Division of Hematology‐Oncology Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea

4. Division of Hematology‐Oncology Department of Medicine Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon Korea

5. Department of Digital Health SAIHST Sungkyunkwan University Seoul Korea

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/eji.202048534

Reference30 articles.

1. The biology and management of non-small cell lung cancer

2. Non-small cell lung cancer: current treatment and future advances

3. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid‐derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications;Immunity, Inflammation and Disease;2024-09

2. Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours;Clinical and Translational Medicine;2024-08

3. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis;Frontiers in Immunology;2024-05-24

4. Regulatory role of CD39 and CD73 in tumor immunity;Future Oncology;2024-04-23

5. CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line;Journal of Translational Medicine;2024-04-03